
    
      Eligible patients are randomized into 2 groups: chest wall and supraclavicular nodal
      +-axillary plus internal mammary nodal irradiation, and chest wall and supraclavicular nodal
      +-axillary nodal irradiation. The prescription dose is 50 Gy in 25 fractions over 5 weeks or
      43.5Gy in 15 fractions over 3 weeks.

      During and after radiotherapy, the patients are followed and the efficacy and toxicities of
      radiotherapy are evaluated.
    
  